DEERFIELD MANAGEMENT COMPANY, L.P. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001009258

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q3 2024 · 439 positions · Total reported value $6.31B · Top-10 concentration 57.3% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 38.6% · 10 new · 12 cut · 12 exited

Active Share (vs S&P 500): 99.6% · vs QQQ: 99.9% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +17.1% · vs SPY +2.2% · Prev Value $7.59B — last quarter positions weighted by this quarter price moves · ranking

In its Q3 2024 13F filing, DEERFIELD MANAGEMENT COMPANY, L.P. disclosed 439 equity positions with a combined reported value of $6.31B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 57.3% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2024 were NUVL ($2.05B), VTRS ($278.56M), CNC ($199.66M). By sector, the heaviest allocations are Health Care 52.9%, Technology 2.7%. Versus the prior quarter, allocation shifted toward Other (+0.5pp) and away from Health Care (-0.5pp).

Versus the prior quarter, DEERFIELD MANAGEMENT COMPANY, L.P. opened 10 new positions, trimmed 12 and fully exited 12, a turnover rate of 38.6% of positions. The portfolio's overlap with the prior quarter was 29% of names.

The largest new positions opened in Q3 2024 were INDV ($49.65M), BCAX ($45.72M), SVRA ($27.41M).

Of the 12 positions fully exited versus the prior quarter, the largest were GILD ($102.30M), APGE ($12.95M), ITOS ($10.73M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2024)

  • INDV INDIVIOR PHARMACEUTICALS INC · $49.65M
  • BCAX BICARA THERAPEUTICS INC · $45.72M
  • SVRA Savara Inc · $27.41M
  • ZBIO ZENAS BIOPHARMA INC COM · $26.44M
  • PCVX VAXCYTE INC · $25.71M
  • DYN DYNE THERAPEUTICS INC · $15.65M
  • RXRX RECURSION PHARMACEUTICALCLASS A · $15.26M
  • CON CONCENTRA GROUP HOLDINGS PAREN COMMON STOCK · $14.53M

Fully Exited (vs previous quarter)

  • GILD GILEAD SCIENCES INC · prev qtr: $102.30M
  • APGE APOGEE THERAPEUTICS INC · prev qtr: $12.95M
  • ITOS ITEOS THERAPEUTICS INC · prev qtr: $10.73M
  • SLDB SOLID BIOSCIENCES INC COM NEW · prev qtr: $9.89M
  • EYPT EYEPOINT INC · prev qtr: $7.64M
  • GUTS FRACTYL HEALTH INC · prev qtr: $3.56M
  • CABA CABALETTA BIO INC · prev qtr: $3.47M
  • DRI DARDEN RESTAURANTS INC · prev qtr: $2.17M

Insider Transactions (Form 4)

Latest DEERFIELD MANAGEMENT COMPANY, L.P. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-07-15 D Nuvalent, Inc. 3,444 $124.00 SEC filing
2026-07-15 U Nuvalent, Inc. 5,146 $124.00 SEC filing
2026-07-15 D Nuvalent, Inc. 650,000 $124.00 SEC filing
2026-07-15 D Nuvalent, Inc. 8,299,225 $124.00 SEC filing
2026-06-16 Award Nuvalent, Inc. 3,444 — SEC filing
2026-06-11 Conversion Parabilis Medicines, Inc. 407,132 — SEC filing
2026-06-11 Conversion Parabilis Medicines, Inc. 260,992 — SEC filing
2026-06-11 Conversion Parabilis Medicines, Inc. 149,238 — SEC filing

All insider transactions →

Fund Profile

Deerfield Management Company, L.P. is a New York-based hedge fund founded by Marianne and James Chadwin, known for its quantitative and fundamental research approach focused primarily on healthcare and biotechnology investments.

Investment Approach

Combines quantitative analysis with fundamental research

Specializes in healthcare and biotechnology sectors

Utilizes both public and private investment strategies

Asset Classes & Strategy

Primarily focused on long/short equity positions

Specializes in healthcare and biotechnology investments

Also invests in other sectors with strong fundamental research

Key Personnel

Marianne Chadwin (Co-founder)

James Chadwin (Co-founder)

Team of experienced portfolio managers and researchers

AUM & Performance

Manages approximately $19.1 billion in assets under management

Performance data not publicly disclosed

All information is based on publicly available SEC filings and company disclosures.

Sector Allocation

Health Care 52.9%
Technology 2.7%
Financials 0.4%
Other 40.2%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 19.99M $2.05B 32.42%
32.42%
Hold
2 23.99M $278.56M 4.42%
4.42%
Add
3 2.65M $199.66M 3.17%
3.17%
Hold
4 3.41M $170.29M 2.70%
2.70%
Add
5 7.85M $166.53M 2.64%
2.64%
Add
6 174.36M $165.76M 2.63%
2.63%
Add
7 11.08M $160.63M 2.55%
2.55%
Hold
8 1.32M $151.70M 2.40%
2.40%
Add
9 21.23M $139.07M 2.20%
2.20%
Hold
10 4.95M $138.11M 2.19%
2.19%
Hold
11 2.91M $132.09M 2.09%
2.09%
Reduce
12 10.85M $128.31M 2.03%
2.03%
Hold
13 6.23M $123.85M 1.96%
1.96%
Reduce
14 9.71M $109.06M 1.73%
1.73%
Reduce
15 15.61M $106.01M 1.68%
1.68%
Hold
16 5.41M $105.74M 1.68%
1.68%
Hold
17 70.00M $103.04M 1.63%
1.63%
Hold
18 2.59M $82.18M 1.30%
1.30%
Add
19 4.91M $77.07M 1.22%
1.22%
Reduce
20 1.92M $73.02M 1.16%
1.16%
Add
21 8.14M $61.83M 0.98%
0.98%
Hold
22 1.78M $57.40M 0.91%
0.91%
Reduce
23 874.80K $55.01M 0.87%
0.87%
Reduce
24 3.28M $54.91M 0.87%
0.87%
Hold
25 151.57K $50.71M 0.80%
0.80%
Hold
26 1.02M $50.28M 0.80%
0.80%
Hold
27 5.09M $49.65M 0.79%
0.79%
New
28 1.78M $47.54M 0.75%
0.75%
Reduce
29 1.80M $45.72M 0.72%
0.72%
New
30 614.89K $44.22M 0.70%
0.70%
Reduce
31 1.41M $40.62M 0.64%
0.64%
Hold
32 3.74M $40.44M 0.64%
0.64%
Hold
33 145.00K $39.88M 0.63%
0.63%
Add
34 5.00M $39.48M 0.63%
0.63%
Hold
35 2.73M $38.50M 0.61%
0.61%
Hold
36 2.03M $37.63M 0.60%
0.60%
Add
37 2.82M $37.62M 0.60%
0.60%
Hold
38 844.41K $37.06M 0.59%
0.59%
Hold
39 2.62M $36.46M 0.58%
0.58%
Reduce
40 1.51M $34.07M 0.54%
0.54%
Add
41 850.70K $32.10M 0.51%
0.51%
Add
42 9.07M $30.10M 0.48%
0.48%
Add
43 3.03M $28.19M 0.45%
0.45%
Add
44 6.71M $27.58M 0.44%
0.44%
Hold
45 6.47M $27.41M 0.43%
0.43%
New
46 1.58M $26.76M 0.42%
0.42%
Add
47 663.85K $26.53M 0.42%
0.42%
Hold
48 1.56M $26.44M 0.42%
0.42%
New
49 240.22K $26.36M 0.42%
0.42%
Hold
50 225.00K $25.71M 0.41%
0.41%
New

FAQ

What did DEERFIELD MANAGEMENT COMPANY, L.P. buy in 2024-Q3?

In its 2024-Q3 13F filing, DEERFIELD MANAGEMENT COMPANY, L.P. reported 439 equity positions worth $6.31B in aggregate; its largest disclosed positions were NUVL ($2.05B), VTRS ($278.56M), CNC ($199.66M).

How large is DEERFIELD MANAGEMENT COMPANY, L.P.'s portfolio?

DEERFIELD MANAGEMENT COMPANY, L.P. reported $6.31B of long equity holdings across 439 positions as of 2024-Q3. Top-10 holdings account for 57.3% of reported value.

What is DEERFIELD MANAGEMENT COMPANY, L.P.'s investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/deerfield-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →